Cost effectiveness analysis provides a tool for evaluating allocation of resources by characterising different healthcare interventions in terms of the extra cost per added unit of health benefit (box 1). 1 Such analyses are being used increasingly to set national and international health priorities. The UK's National Institute for Clinical Excellence, for example, is charged with guiding decisions on use of new and existing technologies in the NHS, based in part on cost effectiveness considerations. 2 3 In recent years innovation in healthcare technology has occurred at an unprecedented pace for some problems, with new options rapidly supplanting existing interventions. 4 We explore how cost effectiveness analysis could be extended to reflect evolving technologies, and how accounting explicitly for future treatment prospects might affect a typical analysis, using treatment for hepatitis C virus (HCV) infection as an example.
Treatment for hepatitis C virus infection
An estimated 2.7 million Americans and 6.7 million Europeans have chronic HCV infection and are at risk of cirrhosis, end stage liver disease, and liver cancer. [7] [8] [9] Treatment decisions are complicated by variable progression rates and require difficult trade-offs between costs, side effects, and uncertain clinical benefits. [10] [11] [12] Various treatments have emerged in recent years, and a series of decision analyses have examined their cost effectiveness (table 1) . Analyses typically have found that each new treatment has an attractive cost effectiveness ratio compared with many common interventions. Most ratios, in fact, have fallen below $10 000 (£5607, €8218)/QALY compared with the next most effective option. Given the rapid evolution of treatments for HCV infection, this example offers an illustration of how anticipated technological changes can be used to enrich conventional cost effectiveness analyses.
Box 1: Cost effectiveness analysis
The basic principle of a cost effectiveness analysis is that all consequences of decisions should be identified, measured, and valued. Cost effectiveness analysis provides a formal framework for comparing the relation between the health and economic consequences of different healthcare interventions. The results are summarised as an incremental cost effectiveness ratio. In this ratio, the net change in health outcomes associated with a particular strategy (compared with an alternative) is included in the denominator, typically expressed as quality adjusted life years (QALYs), and the net change in costs or resource use with a particular strategy (compared with an alternative) is included in the numerator. The incremental cost effectiveness ratio for a strategy is calculated in reference to the next most effective option, excluding strategies that are dominated (those with higher costs and lower benefits than other options) or weakly dominated (those with higher incremental cost-effectiveness ratios than more effective options). 5 Interventions having incremental ratios of $50 000 (£27 500, €40 000) or $100 000 per QALY in the United States, or £30 000 (€44 000, $55 000) per QALY in the United Kingdom, are usually regarded as cost effective.
Modelling the natural course of infection
We developed a Markov model (box 2) of the natural course of HCV infection (figure), incorporating assumptions similar to those used previously. [12] [13] The model includes stages of fibrosis 14 leading to clinical cirrhosis and its complications (such as decompensated liver disease and primary liver cancer), and the possibility of liver transplantation. Details on the model and data sources are on bmj.com.
Retrospective analysis
We begin by travelling back in time to 1996, to revisit the decision problem confronting a patient with chronic HCV infection considering interferon monotherapy, the only approved treatment at that time. Adopting the conventional assumption that the "no treatment" strategy excludes the downstream potential for improved therapies, we calculated the incremental cost effectiveness ratio of monotherapy as $8700/ QALY gained compared with no treatment (see bmj.com for details of the model). With the benefit of hindsight, however, we might ask whether no treatment was the only relevant comparator. In other words, should the alternatives to immediate treatment also have included deferred treatment?
A previous study considered one important element of this question, investigating watchful waiting with periodic liver biopsy versus immediate empirical treatment for chronic HCV infection. 17 The authors found that immediate treatment was cost effective compared with biopsy management. We focus on an additional facet of this question-waiting and watching for technological innovation. For a patient in 1996, how would anticipation of imminent advances in treatment have changed the decision problem?
Perfect foresight scenario
As a starting point, consider a perfect foresight scenario, in which a person must decide between immediate treatment, deferred treatment, or no treatment but we assume perfect knowledge about the timing and nature of a future improved treatment. Specifically, we assume combination therapy with interferon alfa and ribavirin would be available within three years and provide sustained viral clearance in 42% of treated patients versus 11% with monotherapy. To bias towards immediate monotherapy, we assume combination therapy will be more costly ($11 800 v $2500), have more severe side effects (yielding an average loss equivalent to 27 healthy days v 18), and that monotherapy will not reduce the effect of subsequent retreatment with combination therapy, which would also be provided after three years to people who had not responded to monotherapy.
The results provide a sharp contrast to our naïve analysis using the conventional comparison with no treatment. With perfect knowledge of a future more effective regimen, a strategy of waiting three years for the new treatment would have lower costs and greater benefits than immediate treatment -that is, would "dominate" immediate treatment in the cost effectiveness idiom (table 2) .
With the key temporal component of this example, an important factor is the degree to which people "discount" the value of future consequences. Standard practice in cost effectiveness analysis applies annual discount rates of 3-5%, and the first set of results in table 2 reflects a 3% discount rate. Delaying treatment would defer costs and side effects but would also allow the disease to progress. If future consequences are discounted, the relative costs of immediate treatment are higher because of the timing; without discounting, costs are similar. For health outcomes, discounting reduces the advantages of immediate therapy because the benefits of treatment relate largely to averting future disease outcomes (discounting therefore compresses incremental gains from earlier treatment) and the negative effects of treatment (toxicities and adverse events) count less for deferred treatment when These results depend on several other key variables, including rates of progression of disease, costs and adverse outcomes associated with different regimens, and timing of new treatment options. Since this case is intended to illustrate a more general methodological question, we present just one example of the sensitivity of the perfect foresight results to important assumptions in the model. When we vary the year in which an improved treatment arrives, immediate treatment offers lower benefits than deferred treatment (at higher costs, making immediate treatment a "dominated" strategy) even if improvements are up to five years away. Moving from a one year to a five year delay, the difference in overall benefits between immediate and deferred treatment ranges from − 0.03 to − 0.002 QALYs-that is, losses equivalent to 110 healthy days if a new treatment would arrive in one year or one healthy day if the treatment were five years away.
Relaxing assumption of perfect foresight
The above analysis is based on an unrealistic assumption of perfect knowledge of future treatments. However, uncertainty about emerging treatments can be incorporated in a decision analysis framework in the same way that other uncertain outcomes, such as developing cirrhosis, are captured. Define p as the probability of a new treatment being available in three years (with the specifications of combination therapy). In the deferred treatment strategy, we assume that individuals receive combination therapy in year 3 with probability p, or will fall back on monotherapy if no new treatment emerges that year, with probability (1 − p). In the immediate treatment strategy, individuals receive monotherapy now, but may (with probability p) have access to combination therapy in year 3, in the event of non-response or relapse. Allowing for this uncertainty, immediate treatment remains dominated by deferred treatment provided that p > 50%. The probability of a new treatment must be 30% or lower for the incremental cost effectiveness of immediate monotherapy to fall below $50 000/QALY (table 3) .
We have examined different scenarios regarding the timing and likelihood of better treatment separately, but we may also combine these two dimensions. For example, imagine that the cumulative probability of an improved treatment rises linearly over time so that there is a 10% chance of the new treatment emerging in one year, 20% in two years, and so on, up to 50% in five years. In this scenario, the incremental costs of immediate treatment compared with deferred treatment would be $800, with incremental benefits of 0.007 QALYs (less than 3 days), implying an incremental cost effectiveness ratio of more than $115 000/ QALY-that is, more than a 13-fold increase over the assumption of no potential improvements in treatment.
Conclusion
Our analysis shows that taking account of possible future advances in treatment can change conclusions about the cost effectiveness of current interventions for conditions where technology is evolving rapidly. We have presented a simple model of HCV infection that does not do justice to its complex natural course or the nuances of treatment decisions because we wanted to illustrate a more general problem. Certain key features of the problem make consideration of evolving technologies important to economic evaluations, including progression over a relatively long period, uncertain efficacy and toxicity of current treatment, and steady scientific progress toward new treatments. Other conditions that share one or more of these features include chronic lymphocytic leukaemia, cystic fibrosis, primary pulmonary hypertension, and Parkinson's disease. Our approach will be less relevant for conditions that require urgent treatment (for example, acute renal failure) or have current treatments that are very effective and well tolerated (for example, acute cardiac ischaemia).
Technological change is one of many factors that can influence decisions regarding optimal timing of treatment. Incorporating the interactions between these various factors will enrich the clinical relevance of the analysis and enhance its utility in decision making. Quantifying uncertainties regarding technological innovation is methodologically challenging. Although prospective assessment of probabilities that specific improvements will occur is difficult, however, the implicit alternative is to assign them all probabilities of 0. At a minimum, plausible predictions of changes Development of sound clinical guidelines, public health policy, and investments for new technology will require careful consideration of the incremental benefits, harms, and costs associated with new interventions-including those not yet discoveredcompared with existing ones. Even at this early stage, we encourage analysts to model explicitly the full spectrum of alternative options, so that decision makers have estimates of their costs, benefits, and risks (including associated uncertainties) when faced with difficult choices about imperfect treatment. Minimally, economic evaluations should make explicit, and justify, the assumptions that are otherwise implicit, including no development of alternative technologies and no change in costs for existing technologies.
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In a previous study, 4 we used progression parameters that were age-and sex-specific and were empirically calibrated to observed epidemiologic data. 22 For simplicity in the present study, we have taken an average rate of fibrosis progression based on the literature. [6] [7] [8] Other rates and probabilities determining progression in the model were derived from published studies (table A1) .
Estimates for treatment efficacy were computed from pooled results of randomized, controlled trials (table A1). [14] [15] [16] [17] [18] Based on accumulated evidence of a strong link between virological and histological endpoints, [23] [24] [25] [26] [27] [28] [29] the principal endpoint of interest in most studies has been clearance of HCV RNA, referred to as a virological response, measured both at the completion of treatment (end-of-treatment response) and six months after treatment completion (sustained response). We assumed the following: (1) chronic HCV infection may resolve spontaneously or through successful treatment, in either case implying clearance of HCV RNA; (2) spontaneous resolution occurs only in individuals without fibrosis; (3) patients with sustained response to treatment do not experience subsequent histologic progression of fibrosis.
Annual costs for patients in each of the clinical states in the model (table A2) were derived from a published study 1 that included detailed estimates of resource utilization, including hospitalizations, out- 14;15 0.67 Treatment mortality probability 19 0.0005 Liver transplant probability 1 0.031 * Annual rates are converted into annual probabilities in the model. † Remission occurs from the "no fibrosis" state only. ‡ Fibrosis progression rate applies to progression from no fibrosis to portal fibrosis without septa, from no septa to few septa, and so on, including progression from numerous septa without cirrhosis to cirrhosis.
patient visits, laboratory tests and medications and interventions. Treatment costs were based on average wholesale drug costs, 20 combined with previously published cost estimates for clinic visits, laboratory tests and the treatment of adverse events. 3 The costs of therapy accounted for the discontinuation of treatment in patients who did not experience a virological response after 12 weeks of monotherapy or 24 weeks of combination therapy, and also in patients who suffered moderate to severe adverse events. 3 The costs of time spent receiving medical care have not been included in the model, although they were assumed to be small relative to the costs of medications and treatment interventions.
Health-related quality of life weights for the different health states in the model (table A2) were drawn from a previous study that elicited values from a panel of hepatologists. 2 Weights for HCV-related states were assumed to be independent of other comorbidities. The quality of life weight for a given age, sex and HCV state was computed as the product of the weight associated with an HCV-specific health state and an average age-and sex-specific quality weight obtained from published data. 30 Previous estimates of the reduction in quality of life (or disutility) associated with treatment side effects have spanned a wide range, from 0.02 to 0.50. 2;31 We used a conservative estimate of 0.05 for the disutility of interferon monotherapy and assumed the disutility of combination therapy was 50% greater (0.075) in order to bias the analysis in favor of immediate rather than deferred therapy.
